G6PD and acute myeloid leukemia: This is not the case in rodents (Figure 4), and IDH1mt does not increase the survival of acute myeloid leukemia patients because glucose-6-phosphate dehydrogenase (G6PD) is the major provider of NADPH in white blood cells rather than IDH1 [57,58].